Last reviewed · How we verify
amodiaquine plus sulfadoxine-pyrimethamine
This combination inhibits parasite DNA synthesis and folate metabolism through complementary antimalarial mechanisms.
This combination inhibits parasite DNA synthesis and folate metabolism through complementary antimalarial mechanisms. Used for Malaria (uncomplicated Plasmodium falciparum), Malaria treatment in areas with chloroquine and sulfadoxine-pyrimethamine resistance.
At a glance
| Generic name | amodiaquine plus sulfadoxine-pyrimethamine |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Antimalarial combination |
| Target | Plasmodium DNA synthesis and folate metabolism pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amodiaquine is a 4-aminoquinoline that disrupts parasite DNA and heme polymerization, while sulfadoxine-pyrimethamine inhibits sequential steps in folate synthesis (dihydropteroate synthase and dihydrofolate reductase), preventing nucleotide synthesis in Plasmodium parasites. The combination provides synergistic activity against drug-resistant malaria strains.
Approved indications
- Malaria (uncomplicated Plasmodium falciparum)
- Malaria treatment in areas with chloroquine and sulfadoxine-pyrimethamine resistance
Common side effects
- Nausea and vomiting
- Abdominal pain
- Headache
- Pruritus
- Rash
- Hepatotoxicity
- Agranulocytosis (rare)
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) (PHASE4)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |